Epithelial-mesenchymal Transition Status of Circulating Tumor Cells in Breast Cancer and Its Clinical Relevance

Overview

Journal Cancer Biol Med

Specialty Oncology

Date 2020 Apr 17

PMID 32296584

Citations 12

Authors

Jiaojiao Zhou

Xuan Zhu

Shijie Wu

Jingxin Guo

Kun Zhang

Chunjing Xu

Huihui Chen

Yuxi Jin

Yuting Sun

Shu Zheng

Yiding Chen

Affiliations

Soon will be listed here.

Abstract

Circulating tumor cells (CTCs) play a critical role in cancer metastasis, but their prevalence and significance remain unclear. This study attempted to track the epithelial-mesenchymal transition (EMT) status of CTCs in breast cancer patients and investigate their clinical relevance. In this study, the established negFACS-IF:E/M platform was applied to isolate rare CTCs and characterize their EMT status in breast cancer. A total of 89 breast cancer patients were recruited, including stage 0-III ( = 60) and late stage ( = 29) cases. Using the negFACS-IF:E/M platform, it was found that in human epidermal growth factor receptor 2 (HER2)+ patients, mesenchymal CTCs usually exhibited a high percentage of HER2+ cells. Stage IV breast cancer patients had considerably more CTCs than stage 0-III patients. Among stage 0-III breast cancers, the HER2 subtype included a significantly higher percentage of mesenchymal and biphenotypic (epithelial and mesenchymal) CTCs than the luminal A or B subtypes. Among stage IV patients, CTCs were predominantly epithelial in cases with local recurrence and were more mesenchymal in cases with distant metastasis. By applying a support vector machine (SVM) algorithm, the EMT status of CTCs could distinguish between breast cancer cases with metastasis/local recurrence and those without recurrence. The negFACS-IF:E/M platform provides a flexible and generally acceptable method for the highly sensitive and specific detection of CTCs and their EMT traits in breast cancer. This study demonstrated that the EMT status of CTCs had high clinical relevance in breast cancer, especially in predicting the distant metastasis or local recurrence of breast cancer.

Citing Articles

Effects of Platycodon grandiflorus on doxorubicin resistance and epithelial-mesenchymal transition of breast cancer cells via the p38 mitogen-activated protein kinase pathway.

Yun W, Zhang J, Ji M J Mol Histol. 2024; 55(6):1307-1314.

PMID: 39316256 DOI: 10.1007/s10735-024-10271-9.

MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial-mesenchymal transition in lung adenocarcinoma.

Xia X, Ge Y, Ge F, Gu P, Liu Y, Li P J Cancer Res Clin Oncol. 2024; 150(2):88.

PMID: 38341398 PMC: 10858930. DOI: 10.1007/s00432-024-05614-8.

RIPK1-dependent necroptosis promotes vasculogenic mimicry formation via eIF4E in triple-negative breast cancer.

Li F, Sun H, Yu Y, Che N, Han J, Cheng R Cell Death Dis. 2023; 14(5):335.

PMID: 37217473 PMC: 10203343. DOI: 10.1038/s41419-023-05841-w.

Measuring antigen expression of cancer cell lines and circulating tumour cells.

Mentink A, Isebia K, Kraan J, Terstappen L, Stevens M Sci Rep. 2023; 13(1):6051.

PMID: 37055551 PMC: 10101999. DOI: 10.1038/s41598-023-33179-y.

Acetylated-PPARγ expression is regulated by different genotypes associated with the adipogenic differentiation of polyploid giant cancer cells with daughter cells.

Zhang K, Yang X, Zheng M, Ning Y, Zhang S Cancer Biol Med. 2023; 20(1).

PMID: 36647790 PMC: 9843444. DOI: 10.20892/j.issn.2095-3941.2022.0432.

References

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Alix-Panabieres C, Pantel K . Challenges in circulating tumour cell research. Nat Rev Cancer. 2014; 14(9):623-31. DOI: 10.1038/nrc3820. View

Yao Z, Lu L, Wang R, Jin L, Liu S, Li H . Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol. 2013; 31(1):798. DOI: 10.1007/s12032-013-0798-y. View

Aktas B, Kasimir-Bauer S, Muller V, Janni W, Fehm T, Wallwiener D . Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer. 2016; 16:522. PMC: 4960681. DOI: 10.1186/s12885-016-2587-4. View

Su A, Welsh J, Sapinoso L, Kern S, Dimitrov P, Lapp H . Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001; 61(20):7388-93. View

Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P . Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005; 104(8):1742-50. DOI: 10.1002/cncr.21359. View

Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang C, Angelo M . Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001; 98(26):15149-54. PMC: 64998. DOI: 10.1073/pnas.211566398. View

Coumans F, Ligthart S, Uhr J, Terstappen L . Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res. 2012; 18(20):5711-8. DOI: 10.1158/1078-0432.CCR-12-1585. View

10.

Bednarz-Knoll N, Alix-Panabieres C, Pantel K . Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012; 31(3-4):673-87. DOI: 10.1007/s10555-012-9370-z. View

11.

Cristofanilli M, Hayes D, Budd G, Ellis M, Stopeck A, Reuben J . Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005; 23(7):1420-30. DOI: 10.1200/JCO.2005.08.140. View

12.

Mong J, Tan M . Size-Based Enrichment Technologies for Non-cancerous Tumor-Derived Cells in Blood. Trends Biotechnol. 2018; 36(5):511-522. DOI: 10.1016/j.tibtech.2018.02.010. View

13.

Karabacak N, Spuhler P, Fachin F, Lim E, Pai V, Ozkumur E . Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc. 2014; 9(3):694-710. PMC: 4179254. DOI: 10.1038/nprot.2014.044. View

14.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

15.

Bidard F, Proudhon C, Pierga J . Circulating tumor cells in breast cancer. Mol Oncol. 2016; 10(3):418-30. PMC: 5528978. DOI: 10.1016/j.molonc.2016.01.001. View

16.

Hurvitz S, Hu Y, OBrien N, Finn R . Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 2012; 39(3):219-29. PMC: 3835685. DOI: 10.1016/j.ctrv.2012.04.008. View

17.

Bidard F, Fehm T, Ignatiadis M, Smerage J, Alix-Panabieres C, Janni W . Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2012; 32(1-2):179-88. PMC: 3655223. DOI: 10.1007/s10555-012-9398-0. View

18.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

19.

Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F . Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene. 2011; 31(16):2062-74. PMC: 3330264. DOI: 10.1038/onc.2011.383. View

20.

Rao C, Chianese D, Doyle G, Miller M, Russell T, Sanders Jr R . Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol. 2005; 27(1):49-57. View